Skip to main content

Genetic Technologies Signs on Fifth PPO for Coverage of BrevaGen

NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement with Three Rivers Provider Network, bringing the total number of covered lives with in-network access to the company's BrevaGen breast cancer test to more than 23 million.

Three Rivers is a supplemental preferred provider organization based in Chula Vista, Calif., and provides healthcare benefits to more than 10 million members at more than 1 million sites across the country.

Today's agreement is the fifth that Melbourne, Australia-based GTG has executed with similar US PPOs, it said. Earlier this week the company reported that its third-quarter revenues narrowed 9 percent year over year. It also announced settlement deals with two companies over lawsuits alleging infringement of a patent held by GTG cover non-coding DNA technology.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.